PharmaCyte Biotech, Inc. Quarterly Common Stock, Value, Issued in USD from Q1 2011 to Q2 2024

Taxonomy & unit
us-gaap: USD
Description
Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.
Summary
PharmaCyte Biotech, Inc. quarterly Common Stock, Value, Issued history and growth rate from Q1 2011 to Q2 2024.
  • PharmaCyte Biotech, Inc. Common Stock, Value, Issued for the quarter ending July 31, 2024 was $2.17K, unchanged year-over-year.
Common Stock, Value, Issued, Quarterly (USD)
Common Stock, Value, Issued, YoY Quarterly Growth (%)
Period Value YoY Chg Change % Date Report Filed
Q2 2024 $2.17K $0 0% Jul 31, 2024 10-Q 2024-09-17
Q1 2024 $2.17K +$7.00 +0.32% Apr 30, 2024 10-Q 2024-09-17
Q4 2023 $2.17K +$7.00 +0.32% Jan 31, 2024 10-Q 2024-03-18
Q3 2023 $2.17K +$7.00 +0.32% Oct 31, 2023 10-Q 2023-12-15
Q2 2023 $2.17K +$7.00 +0.32% Jul 31, 2023 10-Q 2023-09-18
Q1 2023 $2.16K +$88.00 +4.25% Apr 30, 2023 10-K 2024-08-13
Q4 2022 $2.16K +$88.00 +4.25% Jan 31, 2023 10-Q 2023-03-16
Q3 2022 $2.16K +$88.00 +4.25% Oct 31, 2022 10-Q 2022-12-14
Q2 2022 $2.16K +$2K +1242% Jul 31, 2022 10-Q 2022-09-14
Q1 2022 $2.07K +$1.91K +1203% Apr 30, 2022 10-K 2023-07-31
Q4 2021 $2.07K -$232K -99.1% Jan 31, 2022 10-Q 2022-03-15
Q3 2021 $2.07K -$231K -99.1% Oct 31, 2021 10-Q 2021-12-14
Q2 2021 $161 -$187K -99.9% Jul 31, 2021 10-Q 2021-09-14
Q1 2021 $159 +$50.00 Apr 30, 2021 10-K 2022-07-28
Q4 2020 $234K +$91.3K +63.9% Jan 31, 2021 10-Q 2021-03-12
Q3 2020 $233K +$100K +75.3% Oct 31, 2020 10-Q 2020-12-11
Q2 2020 $188K +$61.7K +49% Jul 31, 2020 10-Q 2020-09-11
Q1 2020 $109* -$118K Apr 30, 2020 10-K 2021-08-10
Q4 2019 $143K +$30.2K +26.8% Jan 31, 2020 10-Q 2020-03-13
Q3 2019 $133K +$25K +23.2% Oct 31, 2019 10-Q 2019-12-23
Q2 2019 $126K +$17.9K +16.6% Jul 31, 2019 10-Q 2019-09-13
Q1 2019 $119K +$17.3K +17% Apr 30, 2019 10-K 2020-08-13
Q4 2018 $113K +$14.7K +15% Jan 31, 2019 10-Q 2019-03-14
Q3 2018 $108K +$10.8K +11.1% Oct 31, 2018 10-Q 2018-12-14
Q2 2018 $108K +$10.6K +10.9% Jul 31, 2018 10-Q 2018-09-12
Q1 2018 $101K +$10.8K +11.9% Apr 30, 2018 10-K 2019-08-13
Q4 2017 $98K +$10.8K +12.4% Jan 31, 2018 10-Q 2018-03-19
Q3 2017 $97.4K +$12.5K +14.7% Oct 31, 2017 10-Q 2017-12-14
Q2 2017 $97.3K +$12.5K +14.7% Jul 31, 2017 10-Q 2017-09-13
Q1 2017 $90.5K +$12.4K +15.9% Apr 30, 2017 10-K 2018-07-20
Q4 2016 $87.2K +$10.1K +13.1% Jan 31, 2017 10-Q/A 2017-03-13
Q3 2016 $84.9K +$10.2K +13.6% Oct 31, 2016 10-Q 2016-12-02
Q2 2016 $84.9K +$10.6K +14.3% Jul 31, 2016 10-Q 2016-09-06
Q1 2016 $78.1K +$4.85K +6.63% Apr 30, 2016 10-K 2017-07-27
Q4 2015 $77.1K +$6.8K +9.66% Jan 31, 2016 10-Q 2016-03-08
Q3 2015 $74.7K +$5.14K +7.38% Oct 31, 2015 10-Q/A 2016-01-19
Q2 2015 $74.3K +$3.23K +4.54% Jul 31, 2015 10-Q/A 2016-01-19
Q1 2015 $73.3K +$4.21K +6.1% Apr 30, 2015 10-K 2016-07-29
Q4 2014 $70.3K +$10K +16.7% Jan 31, 2015 10-Q 2015-03-13
Q3 2014 $69.6K +$10.8K +18.3% Oct 31, 2014 10-Q 2014-12-15
Q2 2014 $71K +$17.3K +32.3% Jul 31, 2014 10-Q 2014-09-15
Q1 2014 $69.1K +$20.9K +43.3% Apr 30, 2014 10-K/A 2016-01-19
Q4 2013 $60.3K +$14.5K +31.7% Jan 31, 2014 10-Q 2014-03-17
Q3 2013 $58.8K +$14.4K +32.4% Oct 31, 2013 10-Q 2013-12-16
Q2 2013 $53.7K +$11.4K +26.8% Jul 31, 2013 10-Q 2013-09-16
Q1 2013 $48.2K +$6.58K +15.8% Apr 30, 2013 10-K 2014-08-04
Q4 2012 $45.8K +$8.35K +22.3% Jan 31, 2013 10-Q 2013-03-26
Q3 2012 $44.5K +$7.02K +18.8% Oct 31, 2012 10-Q 2012-12-26
Q2 2012 $42.3K +$5.01K +13.4% Jul 31, 2012 10-Q 2012-09-19
Q1 2012 $41.6K +$5.92K +16.6% Apr 30, 2012 10-K 2013-07-29
Q4 2011 $37.4K Jan 31, 2012 10-Q 2012-03-21
Q3 2011 $37.4K Oct 31, 2011 10-Q 2011-12-15
Q2 2011 $37.3K Jul 31, 2011 10-Q/A 2011-09-20
Q1 2011 $35.7K Apr 30, 2011 10-K 2012-08-14
* An asterisk sign (*) next to the value indicates that the value is likely invalid.